严重肢体缺血治疗市场（依治疗方法、设备类型、最终用户和分销管道划分）—2025-2032年全球预测

预计到 2032 年，严重肢体缺血治疗市场将成长至 90 亿美元，复合年增长率为 9.17%。

简要概述影响危重肢体缺血治疗策略和决策流程的关键临床、商业性和营运问题

严重肢体缺血是周边动脉疾病最严重的表现形式，需要协调一致的临床和商业应对措施，整合重组、药物治疗和创伤护理的最新进展。本执行摘要概述了当前的治疗格局，总结了新兴治疗方法和医疗设备的发展趋势，并重点介绍了临床项目设计、供应链协调和市场进入途径方面的战略考虑。本摘要旨在为决策者提供简洁明了、基于证据的观点，以支持其在产品开发、商业规划和卫生经济定位方面的优先排序。

不断发展的临床实践、医疗设备创新和综合护理模式如何重塑保肢治疗路径中的手术选择、供应链策略和采用趋势

危重肢体缺血的治疗模式正在经历变革，临床、技术和政策三大因素的交会正在重新定义治疗路径和资源获取重点。微创血管内技术不断发展，更先进的器械和辅助药物疗法层出不穷，推动治疗流程向分阶段、多学科协作的模式转变，以保肢和功能恢復为核心。同时，影像学、器械设计和术中工具的进步缩短了手术时间，并扩大了血管内修復的适用解剖范围，从而影响治疗施行地点的选择和资源分配。

2025年关税对肢体缺血治疗生态系供应链韧性、筹资策略与采购趋势的影响

2025年实施的关税和贸易措施带来了新的财务和营运动态，相关人员必须应对这些变化，以维持供应的连续性和价格的可预测性。关税带来的成本压力迫使製造商和经销商重新评估筹资策略。这些策略包括製造地多元化、更多依赖区域供应商以及重新评估零件的在地采购程度，以降低跨境课税风险。这些调整会影响库存计划以及与医院、门诊手术中心和专科血管中心的合约条款，因为这些机构都需要可靠的交货时间。

详细的细分资讯揭示了影响采纳、采购和证据生成策略的流程、医疗设备、最终用户和通路。

透过对不同细分市场（治疗方法、医疗设备类型、终端用户环境和分销管道）的深入分析，可以发现细微的机会和商业化路径，这些因素共同决定了治疗方法的采纳和应用。依治疗方法划分，血管内手术包括血管成形术、斑块动脉粥状硬化斑块切除术和支架植入术。血管成形术又分为药物释放型球囊和传统球囊，动脉粥状硬化斑块切除术分为定向、雷射、轨道和旋转技术，支架植入术则包括裸金属支架和药物释放型。药物治疗策略包括抗血小板药物、血栓溶解药物和血管扩张剂，而支持性治疗则涵盖高压氧气疗法、疼痛管理和创伤护理。外科手术对某些患者仍然至关重要，其特征是搭桥手术和切除术，其中搭桥手术可进一步细分为自体静脉移植和人工血管移植。

区域间在监管、报销制度和医疗服务提供者生态系统方面的差异会影响全球区域商业化策略和临床应用模式。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的治疗通讯协定、先进医疗设备的取得以及商业性合作模式都产生了显着影响。在美洲，成熟的血管专科中心和高手术量创造了有利于技术迭代改进和真实世界证据生成的环境。同时，支付方的严格审查和全面的报销模式也促使相关人员证明其在降低再入院率和再次手术率方面取得了可衡量的成效。相较之下，欧洲、中东和非洲地区不同的监管环境和采购模式则要求企业制定适应性强的打入市场策略和区域性的证据材料，以确保获得药品目录收录资格和医院合约。

竞争的根本在于证据生成、综合服务提供和策略伙伴关係关係，以推动采纳和长期机构合作。

在危重肢体缺血领域，竞争定位和企业策略体现了器械创新、临床试验领先地位以及连接外科手术和血管内治疗的伙伴关係关係。主要企业优先投资于循证医学证据的积累、针对性临床医生培训以及基于价值的合同，以证明其在临床和经济终点方面具有优越性或同等疗效。器材製造商与创伤护理提供者之间的策略联盟，以及与学术机构进行关键研究的合作，有助于建构差异化的产品故事，并促进与支付者的谈判。

为医疗设备製造商和服务供应商提供切实可行的策略行动，以加强证据支持、降低供应风险并加速其在各种医疗保健环境中的临床应用。

对于希望加速产品推广并巩固市场地位的产业领导者而言，以下是一些着重于整合临床证据、增强供应链韧性和加强商业性合作的实用建议。首先，应优先产生高品质的真实世界证据，将器械和治疗方法的使用与肢体保留、降低再入院率以及提高整个诊疗流程的效率联繫起来，并推动对多中心註册研究和支付方经济模型的投资，以支持价值评估方面的讨论。其次，应实现製造地和物流网络的多元化，以降低关税风险，确保持续向医院、门诊手术中心和专科血管中心供应产品，同时协商能够反映当地采购情况的灵活商业条款。

我们采用多维度的调查方法，结合专家访谈、全面的二手资料分析和情境测试，以确保获得严谨且切实可行的市场洞察。

本研究采用结构化的多源调查方法，以确保研究的严谨性、透明度和与商业性及临床相关人员的相关性。主要研究包括对临床意见领袖、医院、门诊手术中心和血管专科中心的采购负责人以及医疗设备商业化专家的访谈，以检验临床路径、应用驱动因素和采购重点。次要研究整合了同侪审查文献、临床试验註册资讯、监管申报文件和检验的指南，以验证治疗模式、医疗设备分类和辅助性治疗，同时确保临床结论符合当前的实践和监管标准。

整合临床创新、供应链韧性和商业性可行性，以规划一条实现持续应用和改善肢体挽救效果的路径。

总之，血管内技术的进步、辅助药物治疗以及整合式医疗服务模式的出现，正在重塑肢体缺血危重症的治疗格局，这些因素共同为挽救肢体和改善患者预后创造了机会。策略成功的关键在于临床证据的积累，并结合切实可行的供应链策略和适应性强的商业模式，以满足医院、门诊手术中心和专科血管中心的独特需求。关税相关的压力凸显了透明沟通本地供给能力和到岸成本的重要性，而区域差异则要求制定个人化的打入市场策略和报销策略。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 在再生医学的巨大潜力背景下，自体干细胞疗法在治疗慢性严重肢体缺血的应用正在加速发展。
• 不断变化的健保报销机制对CLI患者获得先进血管内治疗设备的影响
• 将穿戴式灌注监测仪与远端医疗平台整合，以实现肢体缺血的即时管理和提高患者依从性
• 药物释放型球囊越来越多地用于治疗膝下疾病，以减少糖尿病慢性肢体缺血（CLI）患者的血管再阻塞。
• 将动脉粥状硬化斑块切除术切除术与血管内影像学结合，以优化膝下动脉病变的术前准备。
• 开发用于周边动脉疾病的生物可吸收支架：为慢性肢体缺血提供暂时支撑和长期血管修復
• 人们越来越关注用于检测高风险糖尿病患者群体中亚临床週边微血管疾病的早期照护现场诊断筛检工具。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法的危重肢体缺血治疗市场

• 血管内治疗
  • 血管成形术
    • 药物涂层球囊
    • 简单球囊扩张术
  • 动脉粥状硬化斑块切除术
    • 定向斑块动脉粥状硬化斑块切除术
    • 雷射动脉动脉粥状硬化斑块切除术
    • 轨道动脉粥状动脉粥状硬化斑块切除术
    • 旋切动脉粥状硬化斑块切除术
  • 支架置入术
    • 裸金属支架
    • 药物释放型支架
• 药物治疗
  • 抗血小板药物
  • 溶栓治疗
  • 血管扩张剂
• 支持性护理
  • 高压氧气疗法
  • 疼痛管理
  • 创伤护理
• 外科手术
  • 心臟绕道手术
    • 自体静脉移植
    • 合成接枝
  • 切除术

第九章 按器材类型分類的危重肢体缺血治疗市场

• 动脉粥状硬化斑块切除术装置
  • 定向斑块动脉粥状硬化斑块切除术
  • 雷射动脉动脉粥状硬化斑块切除术
  • 轨道动脉粥状动脉粥状硬化斑块切除术
  • 旋切动脉粥状硬化斑块切除术
• 气球
  • 药物释放型球囊
  • 普通气球
• 栓塞保护装置
  • 远端滤器
  • 近端闭塞球囊
• 支架
  • 裸金属支架
  • 覆膜支架
  • 药物释放型支架
• 血管移植
  • 自体静脉移植
  • 合成接枝

第十章 以最终用户分類的危重肢体缺血治疗市场

• 门诊手术中心
  • 医院所属中心
  • 独立中心
• 医院
  • 私立医院
  • 公立医院
• 血管专科中心
  • 医院营运中心
  • 独立中心

第十一章 依通路分類的危重肢体缺血治疗市场

• 直销
• 医院药房
  • 住院病人
  • 门诊病人
• 第三方经销商
  • 零售药房
  • 批发商

第十二章 各地区严重肢体缺血治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 按组别分類的危重肢体缺血治疗市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国严重肢体缺血治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Boston Scientific Corporation
  • Medtronic plc
  • Abbott Laboratories
  • LimFlow SA
  • Terumo Corporation
  • Cynata Therapeutics Ltd
  • Becton, Dickinson and Company
  • Penumbra, Inc.

The Critical Limb Ischemia Treatment Market is projected to grow by USD 9.00 billion at a CAGR of 9.17% by 2032.

Concise framing of clinical, commercial, and operational imperatives shaping treatment strategies and decision pathways for severe peripheral arterial disease care

Critical limb ischemia represents the most severe manifestation of peripheral arterial disease, demanding a coordinated clinical and commercial response that integrates advances in revascularization, pharmacologic management, and wound care. This executive summary frames the contemporary treatment landscape, synthesizes emergent therapeutic and device trends, and highlights strategic considerations for clinical program design, supply chain alignment, and market access pathways. The intent is to equip decision-makers with concise, evidence-driven perspectives that support prioritization across product development, commercial planning, and health economic positioning.

Throughout the analysis, emphasis is placed on the interplay between minimally invasive endovascular innovations and traditional surgical approaches, the growing role of adjunctive pharmacotherapy in limb salvage protocols, and the operational imperatives that influence adoption across hospitals, ambulatory surgery centers, and specialty vascular centers. In addition, the summary examines how distribution models and device portfolios interact with institutional procurement practices, reimbursement dynamics, and clinician preference patterns. Taken together, these themes contextualize how clinical outcomes, cost considerations, and organizational incentives shape the trajectory of treatments for patients at imminent risk of limb loss.

By aligning clinical efficacy with pragmatic commercial pathways, this introduction sets the stage for subsequent sections that detail transformative shifts, tariff impacts, segmentation intelligence, regional dynamics, competitor positioning, and practicable recommendations for industry leaders.

How evolving clinical practices, device innovation, and integrated care models are reshaping procedural choice, supply chain strategies, and adoption dynamics across limb salvage pathways

The treatment landscape for critical limb ischemia is undergoing transformative shifts driven by converging clinical, technological, and policy forces that are redefining care pathways and procurement priorities. Minimally invasive endovascular techniques continue to advance with more sophisticated devices and adjunctive pharmacotherapies, prompting a shift in treatment algorithms toward staged, multidisciplinary approaches that emphasize limb salvage and functional recovery. Concurrently, improvements in imaging, device design, and intraprocedural tools have compressed procedural time and broadened the range of anatomies amenable to endovascular repair, thereby influencing site-of-care decisions and resource allocation.

At the same time, the emergence of integrated care models that combine wound care, hyperbaric therapy, and coordinated pain management is reshaping post-procedural recovery protocols and readmission risk mitigation strategies. These integrated models are increasingly important as payors and providers focus on value-based outcomes and total cost of care. Additionally, supply chain innovations, including strategic distribution partnerships and direct-to-provider models, are altering how hospitals, ambulatory surgery centers, and specialty vascular centers source critical devices and therapies. As a result, manufacturers and service providers must adapt to expedited procurement cycles, heightened documentation requirements, and an increased need for real-world evidence to support adoption.

Collectively, these shifts favor technologies and service models that demonstrably improve limb preservation, reduce repeat interventions, and integrate seamlessly into multidisciplinary care pathways, thereby creating new opportunities for differentiated clinical and commercial positioning.

Implications of 2025 tariff measures on supply chain resilience, sourcing strategies, and procurement dynamics in the critical limb ischemia treatment ecosystem

The imposition of tariffs and trade measures in 2025 has introduced new financial and operational dynamics that stakeholders must navigate in order to maintain supply continuity and pricing predictability. Tariff-driven cost pressures have prompted manufacturers and distributors to revisit sourcing strategies, including the diversification of manufacturing footprints, increased reliance on regional suppliers, and a reevaluation of component localization to mitigate exposure to cross-border levies. These adjustments have implications for inventory planning and contractual terms with hospitals, ambulatory surgery centers, and specialty vascular centers that require dependable delivery timelines.

In response, many organizations are accelerating negotiations to lock in longer-term supply agreements, incorporating clauses that address tariff volatility and adjusting pricing models to preserve margin while maintaining clinical access. At the same time, procurement teams are prioritizing supplier consolidation where possible to leverage purchasing power and manage administrative overhead. Regulatory compliance and customs documentation have become higher priorities as tariff regimes have tightened, necessitating closer collaboration between commercial, regulatory, and logistics functions within device and pharmaceutical firms.

From a strategic perspective, the tariff environment increases the value of localized manufacturing or assembly capacity and heightens the importance of demonstrating cost-effectiveness to institutional buyers. Companies that proactively reengineer supply chains, enhance transparency on landed costs, and offer flexible commercial terms will be best positioned to sustain momentum despite the elevated trade friction.

Detailed segmentation intelligence revealing procedural, device, end-user, and distribution pathways that influence adoption, procurement, and evidence generation strategies

Segment-level insights reveal nuanced opportunities and commercialization pathways across treatment modalities, device types, end-user settings, and distribution channels that collectively determine how therapies are adopted and scaled. Within treatment modality, endovascular procedures encompass angioplasty, atherectomy, and stenting, with angioplasty subdividing into drug coated balloon and plain old balloon, atherectomy differentiating into directional, laser, orbital, and rotational techniques, and stenting comprising bare metal and drug eluting options. Pharmacotherapy strategies include antiplatelet agents, thrombolytics, and vasodilators, while supportive care spans hyperbaric oxygen therapy, pain management, and wound care. Surgical procedures remain critical for select patients and are characterized by bypass surgery and endarterectomy, with bypass further distinguishing autologous vein grafts from synthetic grafts.

Device type segmentation underscores where innovation and procurement attention are concentrated, particularly in atherectomy devices that mirror the procedural subtypes of directional, laser, orbital, and rotational approaches, as well as in balloons that separate into drug coated and plain old varieties. Embolic protection devices, including distal filters and proximal occlusion balloons, and stents ranging from bare metal to covered and drug eluting designs, represent focal points for clinical comparative studies. Vascular grafts, both autologous vein and synthetic, continue to serve important roles in surgical revascularization strategies.

Across end users, differences in operational capacity and purchasing behavior appear between ambulatory surgery centers-both hospital owned and standalone-hospitals split between private and public institutions, and specialty vascular centers that can be hospital owned or independent. Distribution channels vary from direct sales and hospital pharmacies, which operate across inpatient and outpatient settings, to third party distributors serving retail pharmacies and wholesale networks. These segmentation insights highlight where targeted clinical evidence, tailored training programs, and specialized commercial models can unlock adoption and optimize value realization.

How regional regulatory, reimbursement, and provider ecosystem differences shape localized commercialization strategies and clinical adoption patterns globally

Regional dynamics exert a strong influence on treatment protocols, access to advanced devices, and the structuring of commercial engagements across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established centers of vascular excellence and high procedural volumes create an environment receptive to iterative technological improvements and real-world evidence generation, while payer scrutiny and bundle-based reimbursement models push stakeholders toward demonstrating measurable reductions in readmissions and repeat interventions. By contrast, Europe, the Middle East & Africa feature heterogenous regulatory landscapes and procurement models that require adaptable market entry strategies and localized evidence packages to secure formulary placement and hospital agreements.

Across the Asia-Pacific region, rapid capacity expansion, increasing procedural adoption, and a growing focus on domestic manufacturing capacity enable both local innovators and global suppliers to pursue differentiated strategies; however, variations in clinician training, infrastructure maturity, and reimbursement frameworks necessitate targeted educational and market-access investments. Transitional markets across regions also create pockets of unmet need where integrated care pathways-combining endovascular therapy, wound care, and supportive modalities-can produce outsized clinical impact if aligned with local clinical guidelines and procurement cycles.

Taken together, regional insights emphasize the need for flexible commercial strategies that account for differences in regulatory timelines, reimbursement mechanisms, clinician practice patterns, and supply chain constraints to maximize reach and clinical benefit across diverse healthcare systems.

Competitive imperatives centered on evidence generation, integrated service delivery, and strategic partnerships that drive adoption and long-term institutional engagement

Competitive positioning and corporate strategies in the critical limb ischemia ecosystem reflect a mix of device innovation, clinical trial leadership, and partnerships that bridge surgical and endovascular care pathways. Key companies prioritize investments in evidence generation, targeted clinician training, and value-based contracting to demonstrate superiority or parity across clinical and economic endpoints. Strategic alliances between device manufacturers and wound-care providers, as well as collaborations with academic centers for pivotal studies, support differentiated product narratives and facilitate payer negotiations.

Leadership within the landscape is often determined by the ability to deliver comprehensive solutions that span acute procedural tools, adjunctive pharmacotherapies, and post-procedural wound management. Firms that establish robust logistical support, offer integrated training programs for interventionalists and vascular surgeons, and present convincing real-world outcomes data are more likely to secure long-term institutional partnerships. Additionally, companies investing in modular service offerings, such as bundled care pathways or outcome-based agreements, are better placed to respond to purchaser demand for predictable outcomes and cost containment.

Emerging entrants with novel mechanisms or procedural adjuncts can gain traction by targeting niche indications and demonstrating clear incremental benefit, while established players must balance incremental innovation with lifecycle management of core portfolios. Overall, the competitive environment rewards agility in evidence generation, supply reliability, and the ability to align commercial models with shifting procurement priorities.

Practical strategic actions for manufacturers and service providers to strengthen evidence, mitigate supply risk, and accelerate clinical adoption across care settings

For industry leaders seeking to accelerate adoption and strengthen market position, a set of actionable recommendations emphasizes alignment across clinical evidence, supply chain resilience, and commercial engagement. First, prioritize generation of high-quality real-world evidence that links device or therapy use to limb preservation, reduced rehospitalization, and overall care pathway efficiency; invest in multicenter registries and payer-facing economic models to support value discussions. Second, diversify manufacturing and logistics footprints to mitigate tariff exposure and ensure continuity of supply for hospitals, ambulatory surgery centers, and specialty vascular centers, while negotiating flexible commercial terms that reflect regional procurement nuances.

Third, tailor clinician education and product training to the specific procedural subtypes and device configurations in clinical use, with dedicated programs for angioplasty subvariants, atherectomy techniques, stent types, and graft options to reduce variability in outcomes and accelerate procedural adoption. Fourth, build integrated service offerings that combine procedural tools, pharmacotherapy guidance, and wound-care support to simplify implementation for care teams and demonstrate holistic value. Finally, engage proactively with payers and institutional procurement stakeholders to design outcome-based agreements, pilot bundled-care initiatives, and transparent pricing frameworks that emphasize predictable total cost of care.

Collectively, these strategic actions enable companies to reduce adoption friction, demonstrate value across diverse care settings, and secure durable partnerships with major care providers and payers.

Multi-source research methodology combining expert primary interviews, comprehensive secondary analysis, and scenario testing to ensure rigorous and actionable market intelligence

This research employs a structured, multi-source methodology designed to ensure rigor, transparency, and relevance to commercial and clinical stakeholders. Primary research included interviews with clinical thought leaders, procurement officers across hospitals, ambulatory surgery centers, and specialty vascular centers, and device commercialization experts to validate clinical pathways, adoption drivers, and procurement priorities. Secondary research synthesized peer-reviewed literature, clinical trial registries, regulatory filings, and publicly available guidelines to triangulate treatment paradigms, device classifications, and pharmacologic adjuncts, while ensuring that clinical assertions align with contemporary practice and regulatory standards.

Analytical methods integrated qualitative insights with structured segmentation frameworks that capture treatment modality, device type, end-user dynamics, and distribution channels, enabling robust cross-sectional comparisons and identification of adoption inflection points. Scenario analysis assessed the operational impact of trade measures and supply chain disruptions, while sensitivity checks evaluated how evidence thresholds and reimbursement changes could influence adoption timing across different institutional settings. Quality assurance procedures included independent peer review of clinical characterizations and commercial narratives to safeguard against bias and ensure the practicability of recommendations provided to industry leaders.

Overall, the methodology balances clinical fidelity with commercial applicability to deliver insights that are actionable for product, market access, and sales strategy teams.

Synthesis of clinical innovation, supply resilience, and commercial execution that outlines the pathway to durable adoption and improved limb salvage outcomes

In conclusion, the critical limb ischemia treatment landscape is being reshaped by advances in endovascular technology, adjunctive pharmacotherapy, and integrated care delivery models that together create opportunities to improve limb salvage and patient outcomes. Strategic success requires aligning clinical evidence generation with pragmatic supply chain strategies and adaptive commercial models that address the unique needs of hospitals, ambulatory surgery centers, and specialty vascular centers. Tariff-related pressures underscore the importance of localized capacity and transparent landed-cost communication, while regional heterogeneity demands tailored market-entry and reimbursement strategies.

Companies that proactively build robust real-world evidence programs, invest in clinician training across procedural subtypes, and offer integrated solutions combining device, pharmacologic, and wound-care support will be better positioned to secure long-term institutional relationships. Moreover, flexible contracting and outcome-oriented agreements can reduce procurement friction and accelerate adoption in both mature and transitional markets. Looking ahead, the synthesis of clinical innovation with disciplined commercial execution will determine which organizations convert technological advantage into sustained clinical and economic impact.

Taken together, these conclusions provide a roadmap for stakeholders aiming to improve patient outcomes while navigating the complex clinical, regulatory, and commercial environment that defines contemporary limb salvage care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Accelerating adoption of autologous stem cell therapies for chronic critical limb ischemia treatment due to regenerative potential
• 5.2. Impact of evolving reimbursement frameworks on accessibility of advanced endovascular devices in CLI patients
• 5.3. Integration of wearable perfusion monitors and telehealth platforms for real time limb ischemia management and patient adherence
• 5.4. Rising preference for drug eluting balloons in below the knee interventions to reduce restenosis rates in diabetic CLI cohorts
• 5.5. Expansion of atherectomy procedures combined with intravascular imaging modalities to optimize lesion preparation in infra popliteal arteries
• 5.6. Development of bioresorbable scaffolds for peripheral arterial disease offering temporary support and long term vascular healing in CLI
• 5.7. Growing emphasis on early point of care diagnostic screening tools to detect asymptomatic peripheral microvascular disease in high risk diabetic populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Critical Limb Ischemia Treatment Market, by Treatment Modality

• 8.1. Endovascular Procedures
  • 8.1.1. Angioplasty
    • 8.1.1.1. Drug Coated Balloon
    • 8.1.1.2. Plain Old Balloon
  • 8.1.2. Atherectomy
    • 8.1.2.1. Directional Atherectomy
    • 8.1.2.2. Laser Atherectomy
    • 8.1.2.3. Orbital Atherectomy
    • 8.1.2.4. Rotational Atherectomy
  • 8.1.3. Stenting
    • 8.1.3.1. Bare Metal Stent
    • 8.1.3.2. Drug Eluting Stent
• 8.2. Pharmacotherapy
  • 8.2.1. Antiplatelet Agents
  • 8.2.2. Thrombolytics
  • 8.2.3. Vasodilators
• 8.3. Supportive Care
  • 8.3.1. Hyperbaric Oxygen Therapy
  • 8.3.2. Pain Management
  • 8.3.3. Wound Care
• 8.4. Surgical Procedures
  • 8.4.1. Bypass Surgery
    • 8.4.1.1. Autologous Vein Graft
    • 8.4.1.2. Synthetic Graft
  • 8.4.2. Endarterectomy

9. Critical Limb Ischemia Treatment Market, by Device Type

• 9.1. Atherectomy Devices
  • 9.1.1. Directional Atherectomy
  • 9.1.2. Laser Atherectomy
  • 9.1.3. Orbital Atherectomy
  • 9.1.4. Rotational Atherectomy
• 9.2. Balloons
  • 9.2.1. Drug Coated Balloon
  • 9.2.2. Plain Old Balloon
• 9.3. Embolic Protection Devices
  • 9.3.1. Distal Filter
  • 9.3.2. Proximal Occlusion Balloon
• 9.4. Stents
  • 9.4.1. Bare Metal Stent
  • 9.4.2. Covered Stent
  • 9.4.3. Drug Eluting Stent
• 9.5. Vascular Grafts
  • 9.5.1. Autologous Vein Graft
  • 9.5.2. Synthetic Graft

10. Critical Limb Ischemia Treatment Market, by End User

• 10.1. Ambulatory Surgery Centers
  • 10.1.1. Hospital Owned Centers
  • 10.1.2. Standalone Centers
• 10.2. Hospitals
  • 10.2.1. Private Hospitals
  • 10.2.2. Public Hospitals
• 10.3. Specialty Vascular Centers
  • 10.3.1. Hospital Owned Centers
  • 10.3.2. Independent Centers

11. Critical Limb Ischemia Treatment Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. Hospital Pharmacies
  • 11.2.1. Inpatient
  • 11.2.2. Outpatient
• 11.3. Third Party Distributors
  • 11.3.1. Retail Pharmacies
  • 11.3.2. Wholesale Distributors

12. Critical Limb Ischemia Treatment Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Critical Limb Ischemia Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Critical Limb Ischemia Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Boston Scientific Corporation
  • 15.3.2. Medtronic plc
  • 15.3.3. Abbott Laboratories
  • 15.3.4. LimFlow SA
  • 15.3.5. Terumo Corporation
  • 15.3.6. Cynata Therapeutics Ltd
  • 15.3.7. Becton, Dickinson and Company
  • 15.3.8. Penumbra, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-20